Advanced in Hysterectomy

Dr. Jayanthi S. Lea

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
University Of Texas Southwestern Medical Center At Dallas
600 S Main St, 
Fort Worth, TX 
Advanced in Hysterectomy
University Of Texas Southwestern Medical Center At Dallas
600 S Main St, 
Fort Worth, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jayanthi Lea is a Gynecologic Oncologist and an Oncologist in Fort Worth, Texas. Dr. Lea is rated as an Advanced provider by MediFind in Hysterectomy. Her top areas of expertise are Cervical Cancer, Ovarian Cancer, Endometrial Cancer, Hysterectomy, and Lymphadenectomy.

Her clinical research consists of co-authoring 97 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 7 articles in the study of Hysterectomy.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in TX
Hospital Affiliations
Parkland Health & Hospital System
UT Of Texas Southwestern University Hospital - William P. Clements Jr.
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
600 S Main St, Fort Worth, TX 76104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Radiation, Drug
Study Drugs: Atezolizumab, Cisplatin
Study Phase: Phase 1
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) After Prior Platinum Containing First-Line Chemotherapy
A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) After Prior Platinum Containing First-Line Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Other, Drug
Study Drugs: Topotecan Hydrochloride, Veliparib
Study Phase: Phase 1/Phase 2
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cabozantinib S-malate, Nivolumab
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Other, Biological
Study Drug: Vigil
Study Phase: Phase 2
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Device, Drug
Study Drug: Paclitaxel
Study Phase: Phase 3
A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Other, Biological, Drug
Study Drugs: Bevacizumab, Emactuzumab, Paclitaxel
Study Phase: Phase 2
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: July 25, 2023
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
View 9 Less Clinical Trials

97 Total Publications

NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025.
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: August 05, 2025
Similar Doctors
Distinguished in Hysterectomy
Dr. Diane M. Twickler
Radiology | Obstetrics and Gynecology | Medical Genetics
Distinguished in Hysterectomy
Dr. Diane M. Twickler
Radiology | Obstetrics and Gynecology | Medical Genetics

University Of Texas Southwestern Medical Center At Dallas

6201 Harry Hines Blvd, 
Dallas, TX 
 (28.3 miles away)
214-633-5555
Languages Spoken:
English
See accepted insurances

Diane Twickler is a Radiologist and an Obstetrics and Gynecologist in Dallas, Texas. Dr. Twickler is rated as a Distinguished provider by MediFind in Hysterectomy. Her top areas of expertise are Placenta Previa, Polyhydramnios, Placental Insufficiency, Diaphragmatic Hernia, and Hysterectomy.

Distinguished in Hysterectomy
Dr. Liza Johannesson
Transplant Surgery | Obstetrics and Gynecology
Distinguished in Hysterectomy
Dr. Liza Johannesson
Transplant Surgery | Obstetrics and Gynecology

Baylor Scott & White Transplant Services Dallas

3410 Worth St, Ste 950, 
Dallas, TX 
 (32.0 miles away)
972-449-0540
Experience:
20+ years
Languages Spoken:
English

Liza Johannesson is a Transplant Surgeon and an Obstetrics and Gynecologist in Dallas, Texas. Dr. Johannesson has been practicing medicine for over 20 years and is rated as a Distinguished provider by MediFind in Hysterectomy. Her top areas of expertise are Infertility, Mayer-Rokitansky-Kuster-Hauser Syndrome, Mullerian Aplasia, Hysterectomy, and Kidney Transplant.

Distinguished in Hysterectomy
Dr. Catherine Y. Spong
Neonatology | Obstetrics and Gynecology
Distinguished in Hysterectomy
Dr. Catherine Y. Spong
Neonatology | Obstetrics and Gynecology
Ut Southwestern Medical Center, Dept Of Ob-gyn, 5323 Harry Hines Blvd, 
Dallas, TX 
 (28.7 miles away)
214-648-3113
Languages Spoken:
English
See accepted insurances

Catherine Spong is a Neonatologist and an Obstetrics and Gynecologist in Dallas, Texas. Dr. Spong is rated as a Distinguished provider by MediFind in Hysterectomy. Her top areas of expertise are Preeclampsia, Placenta Previa, Gestational Diabetes, Tubal Ligation, and Hysterectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lea's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 20 Advanced Conditions
View All 61 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile